The Genetic Interactions Between Non-alcoholic Fatty Liver Disease and Cardiovascular Diseases

Overview

Journal Front Genet

Date 2022 Aug 29

PMID 36035124

Authors

Nicholas W S Chew

Bryan Chong

Cheng Han Ng

Gwyneth Kong

Yip Han Chin

Wang Xiao

Mick Lee

Yock Young Dan

Mark D Muthiah

Roger Foo

Affiliations

Soon will be listed here.

Abstract

The ongoing debate on whether non-alcoholic fatty liver disease (NAFLD) is an active contributor or an innocent bystander in the development of cardiovascular disease (CVD) has sparked interests in understanding the common mediators between the two biologically distinct entities. This comprehensive review identifies and curates genetic studies of NAFLD overlapping with CVD, and describes the colinear as well as opposing correlations between genetic associations for the two diseases. Here, CVD described in relation to NAFLD are coronary artery disease, cardiomyopathy and atrial fibrillation. Unique findings of this review included certain NAFLD susceptibility genes that possessed cardioprotective properties. Moreover, the complex interactions of genetic and environmental risk factors shed light on the disparity in genetic influence on NAFLD and its incident CVD. This serves to unravel NAFLD-mediated pathways in order to reduce CVD events, and helps identify targeted treatment strategies, develop polygenic risk scores to improve risk prediction and personalise disease prevention.

Citing Articles

Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk.

Ionescu V, Gheorghe G, Bacalbasa N, Diaconu C Biomolecules. 2025; 15(2).

PMID: 40001466 PMC: 11852489. DOI: 10.3390/biom15020163.

Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease Prevalence, Diagnosis, Treatment, and Outcomes: A Narrative Review.

Miller K, Geyer B, Alexopoulos A, Moylan C, Pagidipati N Dig Dis Sci. 2024; 70(1):154-167.

PMID: 39560808 DOI: 10.1007/s10620-024-08722-0.

Sex differences in survival following acute coronary syndrome with and without standard modifiable risk factors.

Anand V, Koh J, Teo T, Chin Y, Mahesh R, Chan M Clin Res Cardiol. 2024; .

PMID: 39531081 DOI: 10.1007/s00392-024-02563-7.

Unraveling the genetic and epigenetic landscape governing intramuscular fat deposition in rabbits: Insights and implications.

Ahamba I, Mary-Cynthia Ikele C, Kimpe L, Goswami N, Wang H, Li Z Food Chem (Oxf). 2024; 9:100222.

PMID: 39290671 PMC: 11406001. DOI: 10.1016/j.fochms.2024.100222.

The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East Asia, South Asia, South-East Asia, Central Asia, and high-income Asia Pacific regions.

Goh R, Chong B, Jayabaskaran J, Jauhari S, Chan S, Kueh M Lancet Reg Health West Pac. 2024; 49:101138.

PMID: 39100533 PMC: 11296249. DOI: 10.1016/j.lanwpc.2024.101138.

References

Basu Ray S . PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease. Adipocyte. 2019; 8(1):201-208. PMC: 6768214. DOI: 10.1080/21623945.2019.1607423. View

Sliz E, Sebert S, Wurtz P, Kangas A, Soininen P, Lehtimaki T . NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects. Hum Mol Genet. 2018; 27(12):2214-2223. PMC: 5985737. DOI: 10.1093/hmg/ddy124. View

Bruschi F, Tardelli M, Einwallner E, Claudel T, Trauner M . PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells. Int J Mol Sci. 2020; 21(22). PMC: 7698885. DOI: 10.3390/ijms21228711. View

Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes T, Thompson J . Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2012; 45(1):25-33. PMC: 3679547. DOI: 10.1038/ng.2480. View

Hollands G, French D, Griffin S, Prevost A, Sutton S, King S . The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ. 2016; 352:i1102. PMC: 4793156. DOI: 10.1136/bmj.i1102. View

Sanyal A, Friedman S, McCullough A, Dimick-Santos L . Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015; 61(4):1392-405. PMC: 4900161. DOI: 10.1002/hep.27678. View

Cooper A . Role of the liver in the degradation of lipoproteins. Gastroenterology. 1985; 88(1 Pt 1):192-205. DOI: 10.1016/s0016-5085(85)80155-4. View

Zhao W, Du F, Zhang M, Sun S, Yu H, Fan D . A new recombinant human apolipoprotein E mimetic peptide with high-density lipoprotein binding and function enhancing activity. Exp Biol Med (Maywood). 2011; 236(12):1468-76. DOI: 10.1258/ebm.2011.011169. View

Dong H, Wang J, Li C, Hirose A, Nozaki Y, Takahashi M . The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J Hepatol. 2007; 46(5):915-20. DOI: 10.1016/j.jhep.2006.12.012. View

10.

Boerwinkle E, Utermann G . Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet. 1988; 42(1):104-12. PMC: 1715322. View

11.

Hu Z, Luo H, Xu Y, Guo J, Deng X, Tong Y . Tumor necrosis factor--alpha gene promoter polymorphisms in Chinese patients with nonalcoholic fatty liver diseases. Acta Gastroenterol Belg. 2009; 72(2):215-21. View

12.

Unalp-Arida A, Ruhl C . Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population. Hepatology. 2019; 71(3):820-834. DOI: 10.1002/hep.31032. View

13.

Santos R, Valenti L, Romeo S . Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis. 2019; 282:110-120. DOI: 10.1016/j.atherosclerosis.2019.01.029. View

14.

Bauer R, Yenilmez B, Rader D . Tribbles-1: a novel regulator of hepatic lipid metabolism in humans. Biochem Soc Trans. 2015; 43(5):1079-84. PMC: 4613491. DOI: 10.1042/BST20150101. View

15.

Krawczyk M, Jimenez-Aguero R, Alustiza J, Emparanza J, Perugorria M, Bujanda L . PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surg Obes Relat Dis. 2016; 12(10):1838-1846. DOI: 10.1016/j.soard.2016.06.004. View

16.

Armstrong M, Adams L, Canbay A, Syn W . Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2013; 59(3):1174-97. DOI: 10.1002/hep.26717. View

17.

Kallio M, Salmenpera L, Siimes M, Perheentupa J, Gylling H, Miettinen T . Apoprotein E phenotype determines serum cholesterol in infants during both high-cholesterol breast feeding and low-cholesterol formula feeding. J Lipid Res. 1997; 38(4):759-64. View

18.

Naik A, Kosir R, Rozman D . Genomic aspects of NAFLD pathogenesis. Genomics. 2013; 102(2):84-95. DOI: 10.1016/j.ygeno.2013.03.007. View

19.

Laursen T, Hagemann C, Wei C, Kazankov K, Thomsen K, Knop F . Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World J Hepatol. 2019; 11(2):138-149. PMC: 6393715. DOI: 10.4254/wjh.v11.i2.138. View

20.

Liu D, Peloso G, Yu H, Butterworth A, Wang X, Mahajan A . Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet. 2017; 49(12):1758-1766. PMC: 5709146. DOI: 10.1038/ng.3977. View